- Home
- MBRX vs MEIP Comparison
MBRX vs MEIP Comparison
Compare MBRX & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- MEIP
- Stock Information
- Founded
- MBRX 2015
- MEIP 2000
- Country
- MBRX United States
- MEIP United States
- Employees
- MBRX N/A
- MEIP N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- MEIP Health Care
- Exchange
- MBRX Nasdaq
- MEIP Nasdaq
- Market Cap
- MBRX 12.9M
- MEIP 13.3M
- IPO Year
- MBRX 2016
- MEIP 2003
- Fundamental
- Price
- MBRX $0.31
- MEIP $2.80
- Analyst Decision
- MBRX Strong Buy
- MEIP Hold
- Analyst Count
- MBRX 3
- MEIP 1
- Target Price
- MBRX $5.33
- MEIP N/A
- AVG Volume (30 Days)
- MBRX 5.2M
- MEIP 13.3K
- Earning Date
- MBRX 08-13-2025
- MEIP 05-13-2025
- Dividend Yield
- MBRX N/A
- MEIP N/A
- EPS Growth
- MBRX N/A
- MEIP N/A
- EPS
- MBRX N/A
- MEIP N/A
- Revenue
- MBRX N/A
- MEIP N/A
- Revenue This Year
- MBRX N/A
- MEIP N/A
- Revenue Next Year
- MBRX N/A
- MEIP N/A
- P/E Ratio
- MBRX N/A
- MEIP N/A
- Revenue Growth
- MBRX N/A
- MEIP 33.76
- 52 Week Low
- MBRX $0.25
- MEIP $1.46
- 52 Week High
- MBRX $4.71
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- MBRX 24.39
- MEIP 78.43
- Support Level
- MBRX $0.25
- MEIP $2.21
- Resistance Level
- MBRX $0.42
- MEIP $2.95
- Average True Range (ATR)
- MBRX 0.06
- MEIP 0.15
- MACD
- MBRX -0.03
- MEIP 0.05
- Stochastic Oscillator
- MBRX 13.07
- MEIP 81.48
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.